Azithromycin ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Azasite
Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.
Azithromycin ophthalmic Pregnancy Warnings
This drug should be used during pregnancy only if clearly needed; use is considered acceptable.
US FDA pregnancy category: B
Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Azithromycin ophthalmic Breastfeeding Warnings
Use is considered acceptable; caution is recommended.
Excreted into human milk: Yes
Comments: The effects in the nursing infant are unknown; however, harmful effects would not be expected.
Limited data indicate azithromycin is excreted into breast milk. Due to the low dose and low systemic availability, doses taken by neonates are considered negligible; therefore, breastfeeding is possible during therapy.
See also
References for pregnancy information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2008) "Product Information. AzaSite (azithromycin ophthalmic)." Inspire Pharmaceuticals Inc
References for breastfeeding information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2008) "Product Information. AzaSite (azithromycin ophthalmic)." Inspire Pharmaceuticals Inc
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.